No Data
Jiangxi synergy pharmaceutical (300636.SZ): Rivaroxaban tablets have obtained the pharmaceutical registration certificate.
On November 22, Gelonhui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently received the 'Pharmaceutical Registration Certificate' of Rivaroxaban issued by the National Medical Products Administration. Rivaroxaban is an oral Xa inhibitor, clinically used for the prevention and treatment of thrombotic events in adults and children. According to data from the Yaodu database, the sales of Rivaroxaban tablets in urban, county, and township public hospitals in China in 2023 were approximately 1.74 billion yuan.
Jiangxi Synergy Pharmaceutical (300636.SZ): The active pharmaceutical ingredient of valsartan potassium has been approved by the CDE.
On November 13th, GeLongHui reported that Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently obtained approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) through the 'Active Pharmaceutical Ingredient Registration Information Disclosure' platform. The active pharmaceutical ingredient 'Valsartan Potassium' submitted by the company has been approved by the CDE. Valsartan Potassium is used to treat primary hypertension in adults.
Jiangxi Synergy Pharmaceutical (300636.SZ): The active pharmaceutical ingredient Kelifol passes the pharmaceutical GMP compliance inspection.
Gelong Hui November 12th | Jiangxi Synergy Pharmaceutical (300636.SZ) announced that the company recently received the Jiangxi Provincial Food and Drug Administration's "Jiangxi Provincial Food and Drug Administration Pharmaceutical GMP Compliance Inspection Result Notification (No. 57, 2024)", learned that through on-site inspections and comprehensive evaluation, the company's this inspection of the active pharmaceutical ingredient Kelifuluo complies with pharmaceutical GMP. Kelifuluo is suitable for the local external treatment of mild to moderate atopic dermatitis patients aged 2 and above.
Pacific Securities: Q3 revenue and profit growth of the active pharmaceutical ingredient sector have accelerated significantly, bullish on the high growth trend in Q4 performance.
In Q1 2024, the gross margin of the sector was 36.38%, with a net margin of 12.78%. In Q2, the gross margin was 37.21%, with a net margin of 15.52%. In Q3, the gross margin was 38.27%, +1.88pct year-on-year, +1.06pct quarter-on-quarter, with a net margin of 14.07%, +3.98pct year-on-year, -1.45pct quarter-on-quarter, both gross margin and net margin reaching a new high compared to the same period in the past three years.
Ping An Securities: The supply and demand relationship of active pharmaceutical ingredients continues to improve, and the integration of formulations contributes to long-term growth.
According to IQVIA data, from 2024 to 2028, the global pharmaceutical sales facing patent cliffs and losses are approximately $192 billion, presenting a development opportunity for generic drugs and related specialty active pharmaceutical ingredient companies.
Tonghe Pharmaceutical: Report for the third quarter of 2024
Risks Still Elevated At These Prices As Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Shares Dive 28%
No Data
